期刊
CLINICAL THERAPEUTICS
卷 40, 期 5, 页码 692-703出版社
ELSEVIER
DOI: 10.1016/j.clinthera.2018.03.012
关键词
acute myeloid leukemia; chemotherapy; elderly; health care resource utilization; hospitalization; survival
资金
- Celator Pharmaceuticals, Inc., Jazz Pharmaceuticals plc.
- Jazz Pharmaceuticals
Purpose: Acute myeloid leukemia (AML) disproportionately affects older adults; the prognosis in this subpopulation is generally poor, with variable use of inpatient chemotherapy. This study characterizes treatment patterns, hospitalizations, and outcomes among older patients with AML. Methods: Using the Centers for Medicare & Medicaid Services' 2010-2012 100% Limited Data Set (LDS), data from all hospital claims from fee-for-service Medicare beneficiaries between 60 and 75 years of age with newly diagnosed AML and 1 hospitalization were analyzed. Findings: Among 3700 identified patients with AML, 1979 (53.5%) received chemotherapy. Hospitalization rates were highest initially and then declined over time, irrespective of chemotherapy use. The mean length of initial hospital stay was longer in patients receiving chemotherapy. Intensive care unit admissions occurred in 33% of initial hospitalizations. Factors associated with receiving chemotherapy included younger age, fewer comorbidities, and the absence of prior hematologic disorders. Chemotherapy was associated with significantly increased survival compared with no chemotherapy (P < 0.0001). (C) 2018 The Authors. Published by Elsevier HS Journals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据